Abstract Elastin-specific medial vascular calcification, termed ''Monckeberg's sclerosis,'' has been recognized as a major risk factor for various cardiovascular events. We hypothesize that chelating agents, such as disodium ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), and sodium thiosulfate (STS) might reverse elastin calcification by directly removing calcium from calcified tissues into soluble calcium complexes. We assessed the chelating ability of EDTA, DTPA, and STS on removal of calcium from hydroxyapatite (HA) powder, calcified porcine aortic elastin, and calcified human aorta in vitro. We show that both EDTA and DTPA could effectively remove calcium from HA and calcified tissues, while STS was not effective. The tissue architecture was not altered during chelation. In the animal model of aortic elastin-specific calcification, we further show that local periadventitial delivery of EDTA loaded in to poly(lactic-co-glycolic acid) nanoparticles regressed elastin-specific calcification in the aorta. Collectively, the data indicate that elastin-specific medial vascular calcification could be reversed by chelating agents.
Introduction
''Pathological calcification'' is defined as ectopic deposition of poorly crystalline hydroxyapatite (HA) in soft tissues as observed in blood vessels and cardiac valves [1] . The two areas of calcification seen in arterial tissues include intimal calcification, detected in atherosclerotic plaque present in the intima, and medial arterial calcification (MAC) of elastic layers, detected in patients with diabetes, renal failure, and old age [2] , which is independent of atherosclerosis. Medial calcification, termed ''Monckeberg's sclerosis,'' mostly occurs along the elastic fibers of the media. Its presence correlates well with risk of cardiovascular events and leg amputation in diabetic patients [3] . Currently, no clinical therapy is available to prevent or reverse this type of vascular calcification. Some possible targets to block and regress calcification include local and circulating inhibitors of calcification as well as factors that may ameliorate vascular smooth muscle cell apoptosis [2] . Many of these approaches focus on atherosclerotic calcification. Almost no research has targeted the reversal of elastin-specific medial calcification [2] .
Chelation therapy most often involves the injection of disodium ethylenediaminetetraacetic acid (EDTA), a chemical that binds to or chelates ionic calcium, trace elements, and other divalent cations [4] . Chelation therapy has been touted as an effective treatment to reverse vascular calcification; however, it has been controversial, with opposing views [5] [6] [7] . At present no systemic scientific studies prove that it could reverse cardiovascular calcification [6] . The Trial to Assess Chelation Therapy (TACT), funded by the National Center for Complementary and Alternative Medicine, began in 2003 to determine the safety and effectiveness of EDTA chelation therapy in individuals with coronary artery disease and will end in 2013. First published results showed that intravenous chelation regimen with EDTA reduced the risk of adverse cardiovascular outcomes, but data were not sufficiently convincing to support the routine use of chelation therapy for treatment of patients who have had a myocardial infarction [8] . Unfortunately, the efficacy of various chelating agents in reversing elastin-specific calcification from peripheral vascular tissue has not been studied very well in either in vitro or animal experiments. Here, we tested the hypothesis that common chelating agents, such as disodium EDTA, diethylenetriaminepentaacetic acid (DTPA), and sodium thiosulfate (STS) can remove calcium from HA and calcified tissues without damaging the tissue architecture.
Materials and Methods

Chemicals
HA, EDTA, DTPA, STS, and dichloromethane were all reagent-grade and purchased from Sigma-Aldrich Chemicals (St. Louis, MO). Polyvinyl alcohol (PVA, M.W. = 15 kDa) was purchased from MP Biomedicals (Solon, OH). Poly(L-lactic-co-glycolic acid) (PLGA; lactide:glycolide = 50:50, M.W. = 60-80 kDa) was a gift from Ortec (Piedmont, SC). Stock solutions of EDTA, DTPA, and STS at concentrations of 1, 5, and 10 mg/mL, respectively, were prepared and stored at room temperature. EDTA (5 mg/mL) had a pH of 4.8, while 5 mg/mL DTPA in 0.1 M NaOH had a pH of 12.2.
Tissue Preparation
In order to study the chelation effect on elastin-specific calcification, we wanted to avoid the effect of cells and other extracellular matrix components. Thus, we obtained pure aortic elastin from porcine aorta with standard methods of purification [9] . We used porcine aorta because of easy access and because large quantities of elastin could be obtained. Elastin homology is maintained in all species. In a previous study, we showed that when pure aortic elastin is implanted subcutaneously in rats, it undergoes calcification [10] . Thus, this calcified elastin could be used to study demineralization of elastin-specific calcification by chelating agents.
Calcified porcine aortic elastin (20 days explanted sample, 160-180 lg Ca/mg tissue) was prepared by subdermal implantation of pure porcine aortic elastin in rats as described previously [10] . Briefly, in juvenile male Sprague-Dawley rats (21 days old, 35-40 g; Harlan, Indianapolis, IN) a small incision was made on the back, and two subdermal pouches were formed by blunt dissection. Each rat received two 30 to 40 mg purified elastin implants (one per pouch), which were rehydrated in sterile saline 1-2 hours before implantation. Rats were killed by CO 2 asphyxiation after 20 days implantation, and the implants were retrieved and stored at -80°C. Calcified human aorta (100-300 lg Ca/mg tissue) was from cadavers (age 49-75, both male and female with moderate or severe atherosclerosis) received from Greenville Hospital System (Greenville, SC) following standard dissection techniques. All samples were from the abdominal aorta, just below the renal arteries.
Demineralization of HA HA powder (5 mg) was suspended in 30 mL solution of chelating agents (STS, EDTA, and DTPA; 5 mg/mL, n = 3), while the control group included distilled and deionized (DD) water. At frequent intervals (2, 4, 6, 8, 24 h ), 1 mL of supernatant was withdrawn for Ca assay. Ca content was measured by atomic absorption spectroscopy (model 3030; Perkin-Elmer, Norwalk, CT) as described previously [11] . Briefly, each sample (15-40 mg) was hydrolyzed in 1 mL of 6 N HCl in a test tube at 70°C overnight, and then the solution was completely evaporated at 70°C with a continuous flow of nitrogen in the tube. The residue in the test tube was dissolved in 1 mL of 0.01 N HCl. Hydrolyzed samples were diluted and analyzed by atomic absorption spectroscopy with Ca standards.
Demineralization of Calcified Tissues
Calcified porcine aortic elastin and separately calcified human aorta (10 mg each) were treated with 30 mL chelating solutions (5 mg/mL of STS, EDTA, and DTPA, n = 3). The control group was treated with DD water both for calcified porcine aortic elastin and for calcified human aorta. At certain intervals (2, 4, 6, 8, 24 h for porcine elastin and 8, 12, 24, 36, 48 h for human aorta), 1 mL of solution was withdrawn for Ca assay. Ca content was measured by atomic absorption spectroscopy.
Alizarin Red Stain for Ca
Calcified elastin samples were treated with chelating agents as described previously and then embedded in paraffin blocks, sectioned, and stained for qualitative analysis of Ca with Dahl's alizarin red stain. Since the calcified porcine aortic elastin sample had a more even distribution of calcification, we did the chelation treatment to the bulk calcified elastin first and then made sections and stained the Ca by Dahl's alizarin red stain. For human aorta samples, since the distribution of calcification was nonuniform, we first sectioned samples, located the calcification site, and then did the chelation treatment as described. Calcified human aortas were fixed in 10 % neutral buffered formalin at room temperature for 24 h and processed with an automatic tissue processor (Tissue TEK VIP; Miles, Mishawaka, IN), and 6 lm paraffin sections (n = 12 sections per sample) were soaked in chelating solutions (5 mg/mL of STS, EDTA, and DTPA, n = 3) for 4 h. The control group was treated with DD water (n = 3). Then, slides were stained for 3 min at room temperature with 1 % alizarin red solution and rinsed with distilled water. Sections were counterstained with a 1 % light green solution for 10 s, rinsed with distilled water, and mounted.
Preparation of EDTA-Loaded PLGA Nanoparticles EDTA-loaded PLGA nanoparticles were prepared by a double emulsion method [12] . PLGA (200 mg) was dissolved in 2 mL dichloromethane. EDTA (100 mg) was dissolved in 1 mL deionized water. For the control group, no EDTA was used. Water-in-oil (W1/O) emulsion was prepared with an Omni Ruptor 4000 ultrasonic homogenizer by 20 watts for 5 min. This prepared primary emulsion was subsequently added to 10 mL of 1 % (w/v) PVA solution, and the second emulsion was prepared with a homogenizer (20 watts, 5 min) to obtain water-in-oil-inwater (W1/O/W2) emulsion. Nanoparticles were isolated by solvent evaporation with stirring overnight at room temperature. After three washes of deionized water, nanoparticles were lyophilized and stored at 4°C.
Measurement of Loading Efficiency and Release Profile of EDTA in PLGA Nanoparticles
EDTA-loaded PLGA nanoparticles (5 mg) were dissolved in 1 mL of dichloromethane, 5 mL distilled water was added, and solutions were vortexed for 30 min. After centrifugation at 13,000 rpm for 5 min, the supernatant was collected and the concentration of EDTA was spectrophotometrically measured at 257 nm [13] . EDTA-loaded PLGA nanoparticles (5 mg) were enclosed in dialysis units (Slide-A-Lyzer Ò MINI Dialysis Units; Thermo Scientific, Rockford, IL) and incubated in 30 mL PBS at 37°C with mild agitation. At determined time intervals a 1 mL sample was withdrawn for quantification of EDTA release.
Local EDTA Treatment in the CaCl 2 Injury Model of Vascular Calcification
The CaCl 2 injury model was used to create local arterial calcification (abdominal aortic region) in rats [14] . Ten male Sprague-Dawley rats (5-6 weeks old) were placed under general anesthesia (2-3 % isoflurane), and the infrarenal abdominal aorta was exposed and treated periadventitially with 0.20 mol/L CaCl 2 by placing CaCl 2 -soaked sterile cotton gauze on the aorta for 15 min. The area was flushed with warm saline, and the wound site was closed with sutures. Animals were allowed to recover and placed on a normal diet. One week after the first surgery, the abdominal aorta was re exposed in order to provide treatment directly to the aorta. EDTA-loaded PLGA nanoparticle pellets (30 mg, n = 5) and pure PLGA particle pellets (no EDTA entrapped, n = 5) were placed periadventitially. Rats were allowed to recover. After 1 week, rats were sacrificed and tissues (aorta) and blood were harvested and frozen in liquid nitrogen. Ca and phosphorus levels were measured as described previously [11] .
Statistical Analysis
Results are expressed as means ± standard error of the mean (SEM). Statistical analyses of the data were performed using single-factor analysis of variance. Differences between means were determined using the least significant difference with an a value of 0.05. Asterisks in figures denote statistical significance (P \ 0.05).
Results
Chelation of Ca from HA
Three series of concentrations (1, 5, and 10 mg/mL) of chelating agent solutions (STS, EDTA, and DTPA) were prepared in order to optimize the concentration needed for efficient demineralization. HA powders (10 mg in each group) were suspended with aqueous chelating agent solutions, and the percentage of HA solubilization was calculated (Fig. 1a) . EDTA and DTPA were stronger chelating agent than STS and could remove more Ca from HA (Fig. 1a) . The chelating capacity was dependent on concentrations of chelating agents, with 10 mg/mL showing the highest activity. One milligram of STS, EDTA, or DTPA chelates 1.3 mg of HA; that is, 1 mole of STS, EDTA, or DTPA chelates 0.41, 0.88, or 1.02 mole of HA, respectively.
The concentration of 5 mg/mL of chelating agents was used for further studies [15] . The kinetics of demineralization of HA is shown in Fig. 1b . Most of the chelation and removal of Ca occurred in the first 2 h and continued slowly up to 24 h for EDTA and DTPA. The chelating ability was EDTA [ DTPA [ STS. Since EDTA and DTPA solutions as prepared had pH 4.8 and 12.2, respectively, we examined the effect of pH on the demineralization of HA. HA was suspended in pH buffers (pH 4.8 buffer: 59.0 mL 0.2 M sodium acetate and 41.0 mL 0.2 M acetic acid; pH 12.2 buffer: 50 mL 0.2 M KCl and 20.4 mL 0.2 M NaOH). Ca was not released from HA in the pH range 4.8-12.2, thus suggesting that pH did not play a role in Ca chelation. We also neutralized pH to 7.4 for all chelating solutions and still found similar results of chelation (data not shown).
Chelation of Ca from Calcified Elastin
Calcified aortic elastin (3-5 mg, implanted subdermally in rats to calcify and then isolated) was immersed in 1 mL solution of STS, EDTA, and DTPA with concentrations of 5 and 1 mg/mL for 24 h under vigorous shaking, while the control group was immersed in DD water (n = 3 each group). Remnant Ca levels in the treated elastin fiber were measured by atomic absorption spectroscopy. All chelating agents (STS, EDTA, and DTPA) could remove Ca from the calcified porcine elastin, with the chelating ability sequence EDTA C DTPA [ STS (Fig. 2a) . This is consistent with the previous HA results. For the EDTA treatment we calculated the percentage of Ca loss using the following equation: percentage of calcium loss = [(total calcium in calcified elastin-remnant calcium in calcified elastin)/total calcium in calcified elastin] * 100. Treatment with 1 mg/mL chelating agent for EDTA resulted in about 53 % removal of Ca (Fig. 2a) , while higher EDTA concentration (5 mg/mL) was effective at removing 75 % of Ca (Fig. 2a) . Such an increase in Ca dissolution was not found in the DTPA and STS groups after increasing chelating agent concentrations (Fig. 2a) .
The kinetics of demineralization of calcified elastin for chelating agents with the concentration of 5 mg/mL is shown in Fig. 2b (n = 3 in each group). Both EDTA and DTPA were effective at removal of Ca from calcified porcine elastin, while STS was not effective, which corroborated with the result of HA. However, the kinetics of Ca removal from calcified elastin was much slower than with HA. Longer incubation times lead to continuous removal of Ca so that within 24 h EDTA could remove almost all Ca from calcified elastin (Fig. 2b ). Dahl's alizarin red stain at 24 h of treatment further confirmed that EDTA treatment could remove all Ca, while DTPA was partially successful and STS treatment was ineffective (Fig. 2c) .
Chelation of Ca from Calcified Human Aorta
The kinetics of extraction of Ca from calcified human aorta after treating with chelating agents for 48 h showed that EDTA and DTPA were most effective at removing Ca, while STS was not effectively similar to what was observed in the HA and elastin studies presented above (Fig. 3a) . The kinetics of Ca dissolution was slower, probably due to the denser nature of aortic tissue. To study tissue architecture after chelation, 6 lm sections of human aorta were treated with chelating solutions for 4 hours. Dahl's alizarin red stain (Fig. 3b) for the human aorta sections showed that EDTA and DTPA removed the Ca, while STS treatment was not effective. The tissue sections maintained their typical arterial integral structure. Chelation treatment did not cause delamination or removal of certain parts of the artery for all chelating agent- 
Reversal of Arterial Calcification In Vivo by EDTA
As EDTA was found to be most successful at removing Ca in vitro, we tested its efficacy at removing Ca from calcified aorta in vivo. We prepared PLGA nanoparticles loaded with EDTA so that prolonged (24 h) controlled release of EDTA could be achieved when the nanoparticles were placed close to the calcified aorta. Our in vitro release profile showed that EDTA could be released from PLGA nanoparticles within 3 days (Fig. 4) . Next, we tested if local delivery of EDTA could remove Ca from calcified rat aorta in vivo. We have shown previously that when abdominal aortas of rats were exposed to chemical injury with CaCl 2 it led to elastin-specific MAC with time [16] . We used the 7 day time point after injury for EDTA therapy as substantial calcification is seen in this model at that time [15] . After 7 days, EDTA-loaded PLGA nanoparticle pellets were placed on the aorta. We observed that the PLGA particles were spontaneously absorbed onto the wet abdominal aorta. Seven days after initial EDTA treatment rats were killed to test if local EDTA therapy would reverse elastin calcification. In vivo studies were continued for 7 days to make sure that all of the EDTA could be released and be available to remove Ca. Both Ca and phosphorus levels were significantly lower in the Fig. 3 Demineralization of calcified human aorta. a Kinetics of demineralization of calcified human aorta. All data are presented as means ± SEM, n = 3 per group. b Dahl's alizarin red stain for human aortic sections after treatment with chelating agents, showing efficacy of EDTA and DTPA in removal of calcium EDTA-treated group compared the control group with blank nanoparticles (Fig. 5a ). Histologic analysis also showed that the aortic calcification was greatly reversed in the EDTA-treated group (Fig. 5b) . The Ca and phosphorus levels of the blood plasma in both groups were also quantified, and there was no statistically significant difference between the EDTA-treated group and the pure PLGA control group (Fig. 5c) , clearly suggesting that local delivery of EDTA did not change serum Ca levels, which is often the case with systemic delivery.
Discussion
This is the first study to compare three types of chelating agents (STS, EDTA, and DTPA) used for chelation therapy and their chelating efficiency to remove Ca from HA, calcified aortic porcine elastin, and calcified human aorta. We found that an optimal concentration (1-10 mg/mL) of chelating agents works very well to remove Ca. Our results indicate that both EDTA and DTPA could effectively remove Ca from HA and calcified tissues, while STS was not effective. The tissue architecture was not altered during chelation. Furthermore, our in vivo study demonstrates the proof of the concept for the first time that local delivery of chelating agents such as EDTA could be used to reverse MAC, which is found in arteriosclerosis.
Chelating agents' effectiveness at removing plaques has been advertised and used in certain countries; however, the treatment is not FDA-approved in the United States because of lack of substantial conclusive data. The actual published data are very scarce in both animals and human patients, and no comparative in vitro or animal studies have been performed to demonstrate the Ca-chelating ability of different types of chelating agents (STS, DTPA, and EDTA). Pasch et al. [17] found that STS could probably chelate Ca by forming a soluble Ca thiosulfate complex.
They found that it prevents vascular calcification in uremic rats. But systemic treatment of STS also lowered bone strength in animals, probably due to STS chelation of bone HA. They proved direct Ca chelation by STS through a decline of serum ionized Ca concentrations when exposed to STS in vivo and in vitro. Adirekkiat et al. [18] demonstrated that STS could remove Ca from precipitated minerals and delayed the progression of coronary artery calcification (CAC) in hemodialysis patients. Patients with a CAC score C300 were included to receive intravenous sodium thiosulfate infusion twice weekly posthemodialysis for 4 months. They found that the CAC score did not change significantly with STS treatment but increased substantially in the control group. Our present study shows that the chelating ability of EDTA and DTPA was superior to that of STS to remove Ca from HA-like mineral from calcified elastic tissue.
Disodium EDTA is an amino acid used to sequester divalent and trivalent metal and mineral ions (e.g., lead, mercury, arsenic, aluminum, cobalt, calcium). EDTA binds to metals via four carboxylate and two amine groups [19] . DTPA consists of a diethylenetriamine backbone with five carboxymethyl groups. The molecule can be viewed as an expanded version of EDTA, and it is used similarly for metal chelation. Cavallotti et al. [20] found that intravenous injection of EDTA substantially reduced the extent of Ca deposits in the aortic wall. The general decalcifying mechanism of EDTA may derive from its affinity for divalent ions, especially Ca. Persy et al. [21] demonstrated that calcification in coronary artery disease could be reversed by EDTA-tetracycline long-term therapy. Their hypothesis was that calcification is caused by nanobacteria (NB). In that study, EDTA was given as a rectal suppository base every evening, which was shown to result in high blood EDTA levels sustained for a long time. They proposed that NB were sensitive in vitro to tetracycline and that its action is increased by EDTA dissolving the NB apatitic protective coat. Thus, they concluded that the combination of these drugs might offer a novel treatment for calcific atherosclerotic disease. EDTA has also been proven to reduce the risk of calcific tendinitis of the shoulder [19] if used as a chelating agent. In that study EDTA was administered through single-needle mesotherapy and 15 mi of pulsed-mode 1 MHz ultrasound. Calcifications disappeared completely in 62.5 % of the patients in the study group and partially in 22.5 %; calcifications partially disappeared in only 15 % of the patients in the control group, and none displayed a complete disappearance.
Despite these clinical studies and other EDTA chelation therapies that have gone to clinical trials since 2003 [22] , little basic research has been done to study chelation of HA-like mineral in vitro and in animal studies. This might Fig. 4 EDTA release profile from PLGA nanoparticles. All data are presented as means ± SEM, n = 3 per group be one of the reasons that many negative opinions have been directed toward chelation therapy for removal of Ca from atherosclerotic plaques. Jackson [5] , the editor of International Journal of Clinical Practice, stated that ''Chelation therapy is TACT-less, one wonders why it is still widely used, given the lack of evidence of benefit and potential to do harm (financial gain seems the most likely reason).'' Atwood et al. [6] concluded that ''TACT is unethical, dangerous, pointless, and wasteful. It should be abandoned.'' Fraker et al. [7] concluded that ''Chelation therapy (intravenous infusions of ethylenediamine tetraacetic acid or EDTA) is not recommended for the treatment of chronic angina or atherosclerotic cardiovascular disease and may be harmful because of its potential to cause hypocalcaemia.'' The first randomized clinical trial results published this year for EDTA chelation therapy for coronary artery disease showed some improvements, but the data were not statistically significant to warrant use of chelation therapy for all patients with myocardial infarction [8] . In all clinical studies, chelation therapy was tested to remove Ca from atherosclerotic plaque and improve heart function. Atherosclerotic plaque Ca deposits are due to necrotic tissue core, and removal of Ca from plaque may not remove cholesterol-laden fatty deposits and thus may not be very effective at reducing heart burden. Some have suggested that calcification makes plaques more stable and removal of Ca may make them vulnerable to rupture, which may have led to negative connotations. Our present study with chelating agents is necessary and significant because such therapy was never tested suitably to remove Ca from MAC that occurs in the absence of atherosclerotic plaques in patients with diabetes, end-stage renal disease, and old age. In those cases calcification is observed along the medial elastic layers that make arteries stiff. We envision using chelation therapy for such types of calcification.
Our current results show that both EDTA and DTPA could effectively remove Ca from calcified aortic elastin and calcified human aorta, while STS is not so effective. We have demonstrated that vascular elastin-specific calcification could be reversed by chelating agents in vitro. Our in vivo study in the CaCl 2 injury model, for the first time, shows proof of the concept that chelating agent-loaded PLGA nanoparticles could reverse medial elastin-specific aortic calcification. One criticism of chelation therapy is its effects on serum Ca and bone HA. One previous study of systemic administration of STS in rats showed that such systemic chelation treatment led to decreases of serum Ca and phosphate and compromised bone integrity. The STS treatment group required a significantly lower load to fracture the femur compared to controls [15] . Another study in humans also showed that systemic administration of a chelation agent caused decreases in serum Ca and serum phosphate levels and bone loss by increasing endogenous parathyroid hormone secretion [23] . We consider that chelation therapy could be useful in patients with diabetes and old age to remove elastin-specific calcification if chelating agents such as EDTA are protected in polymeric capsules (such as nanoparticles) and delivered at the site or targeted to vascular calcification. Such treatment would prevent serum Ca chelation and undesired effects on bone density. Our result in rats show that such local EDTA treatment with PLGA nanoparticles completely reversed calcification without damaging vascular structure. This is the first time anyone has shown the effectiveness of local therapy in the reversal of calcification. Such local EDTA treatment also did not change serum Ca and phosphorus levels; thus, it could be used without systemic effects. Our long-term goal is to develop site-specific delivery of the chelating agents with targeted nanoparticles to reverse vascular calcification without causing a negative impact on blood chemistry and bone integrity.
Limitations of Our Study
There are some limitations of our current study. Firstly, for our in vivo chelation study we did not measure plasma levels of other biochemically important metal ions such as chromium, zinc, cobalt, and copper as well as toxic metals such as cadmium and lead, which might be affected by the chelation treatment [24] . We used local delivery of small concentrations of EDTA, and thus, systemic concentrations of chelating agent would be negligible and may not affect other metal ions. Secondly, our animal study results might not be directly applicable to patients with chronic kidney disease or patients on dialysis. In our animal study, rats had normal kidney function, while those patients with arteriosclerosis typically have nonregulated plasma levels of calcium, phosphorus, and other ions [25] . Finally, we did not look at the bone integrity, which might have been affected by the EDTA treatment. Again, because we used local therapy of EDTA at very low concentrations (fourfold lower than used in clinical trials, per kilogram basis) instead of systemic delivery, we hypothesize that it will not affect bone integrity.
In conclusion, we did a comparative in vitro study for three types of chelating agents (STS, EDTA, and DTPA) and showed that EDTA and DTPA could effectively remove Ca from calcified aortic elastin and calcified human aorta. We, for the first time, show that local EDTA treatment with PLGA nanoparticles could reverse calcification without causing vascular damage and change in normal plasma levels of Ca and phosphorus.
